Thursday, April 30, 2020

'Bold' Prostate Cancer Trial Enrolls 'Very, Very Quickly'

'Bold' Prostate Cancer Trial Enrolls 'Very, Very Quickly': For men with early prostate cancer on active surveillance, can the immunotherapy sipuleucel-T (Provenge) reduce grade progression?

No comments:

Post a Comment